Menu Search
Equities

Abnova Taiwan Corp

4133:TAI

Abnova Taiwan Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)29.05
  • Today's Change0.150 / 0.52%
  • Shares traded31.95k
  • 1 Year change-10.62%
  • Beta--
Data delayed at least 20 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Abnova Taiwan Corp share price to rise to 102.08 in the next year from the last price of 29.05.
High251.4%102.08
Med251.4%102.08
Low251.4%102.08

Earnings history & estimates in TWD

On Mar 30, 2018, Abnova Taiwan Corp reported 4th quarter 2017 earnings of 0.22 per share.
Average growth rate-21.43%
Abnova Taiwan Corp reported annual 2017 earnings of 0.97 per share on Mar 30, 2018.
More ▼

Revenue history & estimates in TWD

Abnova (Taiwan) Corporation had 4th quarter 2017 revenues of 111.48m. This missed the 129.00m estimate of the one analyst following the company. The same period last year the company did not report revenues.
Average growth rate-8.31%
Abnova (Taiwan) Corporation had revenues for the full year 2017 of 475.07m. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.